PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY

被引:417
作者
KANTARJIAN, HM
SMITH, TL
OBRIEN, S
BERAN, M
PIERCE, S
TALPAZ, M
ROBERTSON, L
KOLLER, C
ESTEY, E
KEATING, MJ
机构
[1] M.D. Anderson Cancer Center, Houston, TX
[2] Department of Hematology, Box 61, M.D. Anderson Cancer Center, Houston, TX 77030
关键词
LEUKEMIA; MYELOID; CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY;
D O I
10.7326/0003-4819-122-4-199502150-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.
引用
收藏
页码:254 / 261
页数:8
相关论文
共 21 条
[11]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[12]  
KURZROCK R, 1988, NEW ENGL J MED, V319, P990
[13]  
MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
[14]  
OZER H, 1993, BLOOD, V82, P2975
[15]   NEW CONSISTENT CHROMOSOMAL ABNORMALITY IN CHRONIC MYELOGENOUS LEUKEMIA IDENTIFIED BY QUINACRINE FLUORESCENCE AND GIEMSA STAINING [J].
ROWLEY, JD .
NATURE, 1973, 243 (5405) :290-293
[16]   PROGNOSTIC DISCRIMINATION IN GOOD-RISK CHRONIC GRANULOCYTIC-LEUKEMIA [J].
SOKAL, JE ;
COX, EB ;
BACCARANI, M ;
TURA, S ;
GOMEZ, GA ;
ROBERTSON, JE ;
TSO, CY ;
BRAUN, TJ ;
CLARKSON, BD ;
CERVANTES, F ;
ROZMAN, C .
BLOOD, 1984, 63 (04) :789-799
[17]  
TALPAZ M, 1987, BLOOD, V69, P1280
[18]   HEMATOLOGIC REMISSION AND CYTOGENETIC IMPROVEMENT INDUCED BY RECOMBINANT HUMAN INTERFERON-ALPHA-A IN CHRONIC MYELOGENOUS LEUKEMIA [J].
TALPAZ, M ;
KANTARJIAN, HM ;
MCCREDIE, K ;
TRUJILLO, JM ;
KEATING, MJ ;
GUTTERMAN, JU .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (17) :1065-1069
[19]  
TURA S, 1994, NEW ENGL J MED, V330, P820
[20]  
TURA S, 1994, NEW ENGL J MED, V331, P402